BIOCORP Appoints Robert Kilgore as Senior Advisor to Build Its Presence in the United States

Regulatory News:

BIOCORP (Paris:ALCOR) (FR0012788065 – ALCOR / PEA-PME eligible), a French company specializing in the development and manufacturing of innovative medical and drug delivery devices announces the appointment of Robert Kilgore as Senior Advisor.

"We are thrilled to announce the appointment of Robert Kilgore within our company as a Senior Advisor. Robert is a well-known expert in the medical community. His previous senior positions provide the expertise to develop an extensive network in the field of medical devices and his experience and understanding of the U.S. market is going to be a tremendous asset for Biocorp’s development in the United States”, states Jacques Gardette, Biocorp’s President and Founder.

"Throughout my career, I have always had a strong interest for innovative medical devices. Biocorp’s disruptive technology and easy-to-use devices benefit both the patients and healthcare providers. The added value of this technology is considerable and offers substantial growth potential at a time when chronic diseases are becoming a global public health problem. Patients’ care, follow-up and compliance are critical in the treatment of these diseases and Biocorp provides an innovative, simple and efficient solution”, comments Robert Kilgore.

Robert Kilgore has been working in the medical devices and pharmaceutical industries for over 35 years. As Biocorp’s Senior Advisor in the United States, he will be in charge of representing Biocorp to U.S. pharmaceutical and biotech companies and establishing the company’s network locally.

Formerly with Haselmeier GmbH as Managing Director from 2004 to 2012 and President of Haselmeier, Inc. from 2012 to 2015, Robert Kilgore orchestrated the strategic and business development of injection devices developed by the company on a global scale. He supervised the establishment of the first U.S. offices, negotiated multiple development and licensing agreements with U.S. pharmaceutical companies and was the U.S. Agent for FDA regulatory correspondence for medical devices.

Before joining Haselmeier, Robert Kilgore was Senior Vice-President at Meridian Medical Technologies. Inc. (a Pfizer company) from 2000 to 2004 where he was responsible for creating a new pharmaceutical division specializing in the marketing and business development of pharmaceuticals products. From 1996 to 2000 he held the positions of Director of Marketing and Business Development and Director of Advanced Drug Delivery for Becton Dickinson, a global medical technology company.

About BIOCORP

Founded in 2004 in Issoire (near Clermont-Ferrand, France), Biocorp is a French company specializing in the development and manufacturing of medical devices and innovative drug delivery systems. It is listed as ‘Innovative Company’ by the French public investment bank Bpifrance. With over twenty years of experience and more than 30 manufactured products, Biocorp is a key player in the industry, providing drug delivery solutions that meet the evolving needs of patients. Today, Biocorp continues to innovate in the area of medical plastics, its core business, and to market traditional devices (alternative to aluminum capsules, syringe and vial administration systems) that have been an important source of recurring income. Its solid expertise and capacity to innovate have allowed the company to develop new internet-connected products, including: the DataPen, a reusable smart injection pen that automatically transmits data to a mobile app, helping patients to manage their treatment; and treatment management add-ons, which adapt to existing delivery devices and are compatible with most injection pens in the market. The company has a team of 43 employees.

Biocorp is listed on Alternext since July 2015 (FR0012788065 – ALCOR). For more information, please visit: www.biocorp.fr

Follow us on Twitter @BIOCORPSystems

View source version on businesswire.com: http://www.businesswire.com/news/home/20160127005847/en/